Novartis' Psoriasis Drug AIN457 Shows Positive Results In 3 Phase 2 Trials RTT News (RTTNews) - Swiss drug creator Novartis AG (NVS: tidings ) on Monday aforementioned three Phase II trials with AIN457 (secukinumab) showed a quick and important improvement of symptoms in patients with moderate-to-severe speckle psoriasis . Plaque disease of the skin is a ... Novartis Phase II data amusement AIN457 provided rapid and significant relief of ... Reuters (press release) Novartis drug AIN457 helps with psoriasis symptoms Economic present time all 18 news articles » Link To Article
No comments:
Post a Comment